JP2022553421A - がんの処置のための方法および組成物 - Google Patents

がんの処置のための方法および組成物 Download PDF

Info

Publication number
JP2022553421A
JP2022553421A JP2022524928A JP2022524928A JP2022553421A JP 2022553421 A JP2022553421 A JP 2022553421A JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022553421 A JP2022553421 A JP 2022553421A
Authority
JP
Japan
Prior art keywords
chemotherapeutic agents
compound
formula
plag
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553421A5 (https=
Inventor
ヨン ソン，キ
ファ キム，ジェ
ヨン ユン，ソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzychem Lifesciences Corp
Original Assignee
Enzychem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzychem Lifesciences Corp filed Critical Enzychem Lifesciences Corp
Publication of JP2022553421A publication Critical patent/JP2022553421A/ja
Publication of JP2022553421A5 publication Critical patent/JP2022553421A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022524928A 2019-10-28 2020-10-28 がんの処置のための方法および組成物 Pending JP2022553421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926963P 2019-10-28 2019-10-28
US62/926,963 2019-10-28
PCT/IB2020/060104 WO2021084441A2 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2022553421A true JP2022553421A (ja) 2022-12-22
JP2022553421A5 JP2022553421A5 (https=) 2023-11-07

Family

ID=75714907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524928A Pending JP2022553421A (ja) 2019-10-28 2020-10-28 がんの処置のための方法および組成物

Country Status (6)

Country Link
US (1) US20220370397A1 (https=)
EP (1) EP4051260A4 (https=)
JP (1) JP2022553421A (https=)
KR (1) KR20220114532A (https=)
CN (1) CN114650815A (https=)
WO (1) WO2021084441A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144538A1 (en) * 2019-01-07 2020-07-16 Enzychem Lifesciences Corporation Compositions and methods for modulating an inflammatory response
US20220125882A1 (en) * 2019-01-16 2022-04-28 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528277A (ja) * 2013-08-19 2016-09-15 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ モノアセチルジアシルグリセロール化合物を有効成分として含有する血液癌または癌転移抑制用組成物
JP2017515915A (ja) * 2014-05-15 2017-06-15 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 白血球減少症及び血小板減少症に対する治療方法
JP2018508516A (ja) * 2015-03-04 2018-03-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
JP2019501224A (ja) * 2016-01-08 2019-01-17 ユークリセス ファーマシューティカルズ，インコーポレイテッド クロメン化合物および第２活性薬剤の併用薬
JP2019516733A (ja) * 2016-05-20 2019-06-20 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ−１またはＰＤ−Ｌ１阻害剤との併用療法
JP2022526210A (ja) * 2019-01-16 2022-05-24 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283010B1 (ko) * 1997-11-20 2001-04-02 전길자 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
CA2562897C (en) * 2004-04-24 2011-03-15 Sang-Hee Kim Immunomodulating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
KR20190063536A (ko) * 2017-11-30 2019-06-10 주식회사 엔지켐생명과학 1-팔미토일-2-리놀레오일-3-아세틸글리세롤을 포함하는 급성 방사선 증후군의 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528277A (ja) * 2013-08-19 2016-09-15 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ モノアセチルジアシルグリセロール化合物を有効成分として含有する血液癌または癌転移抑制用組成物
JP2017515915A (ja) * 2014-05-15 2017-06-15 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 白血球減少症及び血小板減少症に対する治療方法
JP2018508516A (ja) * 2015-03-04 2018-03-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
JP2019501224A (ja) * 2016-01-08 2019-01-17 ユークリセス ファーマシューティカルズ，インコーポレイテッド クロメン化合物および第２活性薬剤の併用薬
JP2019516733A (ja) * 2016-05-20 2019-06-20 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ−１またはＰＤ−Ｌ１阻害剤との併用療法
JP2022526210A (ja) * 2019-01-16 2022-05-24 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物

Also Published As

Publication number Publication date
US20220370397A1 (en) 2022-11-24
CN114650815A (zh) 2022-06-21
KR20220114532A (ko) 2022-08-17
EP4051260A2 (en) 2022-09-07
WO2021084441A3 (en) 2021-06-10
WO2021084441A2 (en) 2021-05-06
EP4051260A4 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
US12098212B2 (en) Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US20210161928A1 (en) Cancer therapy via a combination of epigenetic modulation and immune modulation
Zhu et al. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
EP3730152A1 (en) Combination drug including tlr7 agonist
KR20190137151A (ko) 병용 요법
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
US20240052061A1 (en) Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
JP2022553421A (ja) がんの処置のための方法および組成物
US20240024317A1 (en) Cancer treatment using bosentan in combination with a checkpoint inhibitor
EP3856251A1 (en) Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
EP3888647B1 (en) Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as combination drug
EP3310746A1 (en) New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol
US20250041286A1 (en) Cancer treatment using ketotifen in combination with a checkpoint inhibitor
JP2023512151A (ja) Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法
WO2024211398A2 (en) Combination treatment for ovarian cancer
RU2846282C2 (ru) Способы и композиции для стимуляции и потенцирования опосредованных т-клетками иммунных ответов посредством adcc-нацеливания cd39-экспрессирующих клеток
CN120346313A (zh) 治疗肿瘤的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250612